In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe.

Abstract

Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (n = 1,211). Contezolid demonstrated potent activity against Staphylococcus aureus (MIC50/90, 0.5/1 mg/liter), coagulase-negative Staphylococcus (MIC50/90, 0.25/0.5 mg/liter), Enterococcus spp. (MIC50/90, 0.5/1 mg/liter), and streptococci (MIC50/90, 1/1 mg/liter). Moreover, methicillin-resistant S. aureus and vancomycin-resistant Enterococcus faecium isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.

• Authors: Cecilia G Carvalhaes, Leonard R Duncan, Wen Wang, Helio S Sader
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 64 Issue 11 (10 20 2020) ISSN: 1098-6596 [Electronic] United States
• PMID: 32778552 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 American Society for Microbiology.

Chemical References

• Anti-Bacterial Agents
• Oxazolidinones
• Pyridones
• contezolid

Topics

• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Europe
• Gram-Positive Bacteria
• Methicillin-Resistant Staphylococcus aureus
• Microbial Sensitivity Tests
• Oxazolidinones (pharmacology)
• Pyridones
• United States